Skip to main content
. 2017 Jun 13;12:4415–4431. doi: 10.2147/IJN.S129989

Figure 6.

Figure 6

Effect of oral ATIQCTPC on tumor weight of S180 mice, thrombosis of rats, serum TNF-α and IL-8 of S180 mice, P-selectin expression of the platelets of the rats receiving anti-thrombotic therapy, and P-selectin expression of the platelets in vitro.

Notes: (A) In vivo oral ATIQCTPC dose dependently inhibits the growth of the tumor of S180 mice (n=12). (B) TNF-α in the serum of S180 mice treated with NS and 0.01 μmol/kg of ATIQCTPC for 10 consecutive days (n=12). (C) IL-8 in the serum of S180 mice treated with NS and 0.01 μmol/kg of ATIQCTPC for 10 consecutive days (n=12). (D) Antithrombotic activity of ATIQCTPC (n=12). (E) In vivo P-selectin expression of the platelets of the rats treated with NS, ATIQC (1 μmol/kg), and ATIQCTPC (1, 0.01, and 0.001 μmol/kg; n=12). (F) P-selectin expression of AA-activated platelets treated with 1 μM of ATIQCTPC in vitro (n=5).

Abbreviations: ATIQCTPC, (6S)-3-acetyl-4-oxo-N-(2-(3,4,5,6-tetrahydroxytetrahydro-2H-pyran-2-carboxamido)ethyl)-4,6,7,12-tetrahydroindolo[2,3-a]quinolizine-6-carboxamide; TNF-α, tumor necrosis factor-α; IL-8, interleukin-8; n, number; NS, normal saline; ATIQC, (S)-3-acetyl-4-oxo-tetrahydroindolo[2,3-a]quinolizine-6-carboxylic acid; AA, arachidonic acid; SD, standard deviation.